XORTX Therapeutics Inc.

XORTX Therapeutics Inc. is a biotechnology company focused on developing drug therapies for conditions related to purine metabolism and elevated serum uric acid levels. Its primary products include oxypurinol, a xanthine oxidase inhibitor aimed at treating gout, as well as therapies for autosomal dominant polycystic kidney disease (ADPKD), diabetic nephropathy, and acute kidney injury linked to respiratory viruses. XORTX operates in the pharmaceutical sector, generating revenue through the development and commercialization of its patented therapies, with a focus on addressing unmet medical needs in kidney health and related diseases.